Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31273641 | 0.91 | GRM5 (0.42) | SQORGRM5CYP11B2SMN1; SMN2CHEK1 | |
| SCHEMBL22562508 | 0.91 | GRM5 (0.42) | SQORGRM5CYP11B2SMN1; SMN2CHEK1 | |
| SCHEMBL23296302 | 0.89 | PDE4A (0.36) | SQORCYP11B2SMN1; SMN2HTTMAPT | |
| SCHEMBL23296368 | 0.87 | TGFBR1 (0.39) | SQORCYP11B2TGFBR1CYP2A6 | |
| SCHEMBL31273433 | 0.86 | SQOR (0.38) | SQORCYP11B2KDM4EALDH1A1PDE4D | |
| SCHEMBL31273231 | 0.85 | CYP11B2 (0.38) | SQORCYP11B2SMN1; SMN2RECQLKDM4E | |
| SCHEMBL23342076 | 0.85 | SQOR (0.38) | SQORCYP11B2KDM4EPDE4D | |
| SCHEMBL31272446 | 0.85 | SQOR (0.38) | SQORCYP11B2KDM4EPDE4D | |
| SCHEMBL31272927 | 0.85 | SQOR (0.39) | SQORCYP11B2KDM4EALDH1A1 | |
| SCHEMBL31273364 | 0.84 | SQOR (0.38) | SQORCYP11B2KDM4EALDH1A1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250359476-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX INC (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12369492-B2 | Composition of matter for use in organic light-emitting diodes | KYULUX, INC. (JP) | 2025-07-22 | — | — | US | disclosed |
| EP-4498784-A2 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | Kyulux, Inc. (JP) | 2025-01-29 | — | — | EP | disclosed |
| EP-3775100-B1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX INC (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-20210135119-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX, INC. (JP) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210135119-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | CRY2, SLCO1B3, NDUFV3 | SQOR 399/4885GRM5 476/4885CYP11B2 1221/4885 |
| US-20250359476-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | CRY2, SLCO1B3, NDUFV3 | SQOR 399/4885GRM5 476/4885CYP11B2 1221/4885 |
| US-12369492-B2 | Composition of matter for use in organic light-emitting diodes | CRY2, SLCO1B3, NDUFV3 | SQOR 399/4885GRM5 476/4885CYP11B2 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.